I-AZD-9291 powder (1421373-65-0) -Ifektri yoMvelisi
I-AASraw ivelisa i-Cannabidiol (CBD) ipowder kunye ne-Hemp ebalulekileyo yeoyile ngobuninzi!

I-AZD-9291

Akukho kalo Udidi:

I-AZD-9291 powder yi-epidermal factor factor receptor (EGFR) tyrosine kinase inhibitor (TKI) ebophelela kwiifom ezithile ze-EGFR (T790M, L858R, kunye ne-exon 19 yokususa) ekhokelela kwisisu somhlaza esingengomncinci (NSCLC) tumors ukulandela unyango kumgca wokuqala we-EGFR-TKIs.

Ingcaciso yeMveliso

Iimpawu ezisisiseko

Igama lemveliso I-AZD-9291 powder
Inani leCAS 1421373-65-0
I-Molecular Formula C28H33N7O2
Ubukhulu beFormula 499.6
Iintetho ezifanayo 1421373-65-0;

osimertinib;

Mereletinib;

AZD9291;

N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide.

Kubonakala I-White ukuya kumhlophe i-crystalline powder
Ukugcina nokuPhatha Gcina kubushushu begumbi phakathi kwama-20 ° C -25 ° C

 

Inkcazo yePowder ye-AZD-9291

I-AZD-9291 powder lonyango ekujolise kulo olujolise kwi-epidermal grow factor receptor (EGFR) T790M ngaphakathi kweseli yomhlaza.

Uhlobo lwe-EGFR ludlala indima ebalulekileyo kuzo zombini iiseli zomhlaza kunye nomhlaza. Olu hlobo lukhokelela kwimveliso yeprotein ye-EGFR. Le protein ihlala iyinxalenye yesixokelelwano seemolekyuli ezihambisa umqondiso oxelela iiseli indlela yokukhula nokwahlulahlula. Utshintsho kuhlobo lwe-EGFR (olubizwa ngokuba kukutshintsha) lunokutshintsha indlela esebenza ngayo iprotein ye-EGFR. Endaweni yokulinda ithuba layo lokuba iseli yahlule okanye ikhule, iprotein ye-EGFR ayikho kulawulo kwaye ibonisa ixesha lonke, oku kungalawulekiyo kwe-EGFR kungakhokelela ekukhuleni okungalawulwayo kweeseli zomhlaza. Iithagethi ze-AZD-9291 zepowder zikhetha iindlela eziguqukayo ze-EGFR, kubandakanya i-t790M, i-L858R kunye ne-exon 19 yokususa. I-AZD-9291 powder iyakhetha ukukhuthaza utshintsho kunye ne-T790M yokumelana nokuguquka, eyona ndlela iqhelekileyo yokuchasana ne-EGFR tyrosine kinase inhibitors.

 

Indlela yeAzd-9291 yePowder yeMisebenzi

I-AZD-9291 powder yi-epidermal factor factor receptor (EGFR) tyrosine kinase inhibitor (TKI) ebophelela kwiifom ezithile ze-EGFR (T790M, L858R, kunye ne-exon 19 yokususa) ekhokelela kwisisu somhlaza esingengomncinci (NSCLC) tumors ukulandela unyango kumgca wokuqala we-EGFR-TKIs. Njengesizukulwana sesithathu se-tyrosine kinase inhibitor, i-AZD-9291 powder icacile kumgcini-wesango u-T790M uguquko olonyusa umsebenzi wokubopha we-ATP kwi-EGFR kunye neziphumo zesifo esingalunganga sesifo esikwinqanaba lokugqibela. Ngapha koko, i-AZD-9291 powder (i-osimertinib) ibonakalisiwe ukuba ilondoloze uhlobo lwasendle lwe-EGFR ngexesha lonyango, ngaloo ndlela kuncitshiswa ukubopha okungachazwanga kunye nokuthintela ityhefu.

 

Isicelo sePowder ye-AZD-9291

I-AZD-9291 powder lonyango lonyango lomhlaza wesifo somhlaza esingelolincinci (NSCLC) ethe yasasazeka kwamanye amalungu omzimba (metastatic). I-AZD9291 isetyenziswa:

▪ Njengonyango lwakho lokuqala ukuba amathumba anento ethile engaqhelekanga yokukhula kwe-epidermal factor factor (EGFR).

▪ Ukuba unohlobo oluthile lwe-EGFR kwaye ngaphambili wawunyangwa ngeyeza le-EGFR tyrosine kinase inhibitor (TKI) elingazange lisebenze okanye elingasasebenziyo.

 

Iimpembelelo ze-AZD-9291 zePowder kunye nesilumkiso

I-AZD-9291 powder kunokubangela iziphumo ebezingalindelekanga ezimandundu, kubandakanya:

Iingxaki zemiphunga. I-AZD-9291 powder inokubangela iingxaki zemiphunga ezinokubangela ukufa. Iimpawu zinokufana neempawu zomhlaza wemiphunga. Tshela ugqirha wakho ngoko nangoko ukuba unayo nayiphi na impawu ezintsha okanye eziya zisanda zemiphunga, kubandakanya nokuphefumla, ukuphefumla kancinci, ukukhohlela, okanye umkhuhlane

Problems iingxaki zentliziyo, kubandakanya ukusilela kwentliziyo. I-AZD-9291 powder inokubangela iingxaki zentliziyo ezinokubangela ukufa. Ugqirha wakho kufuneka ahlole ukusebenza kwentliziyo yakho ngaphambi kokuba uqale ukuthatha i-AZD-9291 powder kwaye ngexesha lonyango njengoko kufuneka. Tshela ugqirha wakho ngoko nangoko ukuba unayo nayiphi na imiqondiso kunye neempawu zengxaki yentliziyo: ukuziva ngathi intliziyo yakho iyagungqa okanye ukubaleka, ukuphefumla kancinci, ukudumba kwamaqatha neenyawo, uzive unentloko

▲ iingxaki zamehlo. I-AZD-9291 powder inokubangela iingxaki zamehlo. Tshela ugqirha wakho ngoko nangoko ukuba uneempawu zengxaki yamehlo enokubandakanya amehlo anamanzi, ubuntununtunu ekukhanyeni, iintlungu zamehlo, ukuba bomvu kwamehlo, okanye utshintsho lombono. Ugqirha wakho angakuthumela ukuba ubone ugqirha wamehlo (ophthalmologist) ukuba ufumana iingxaki zamehlo nge-AZD-9291 powder.

Problems iingxaki zolusu. I-AZD-9291 powder inokubangela iingxaki zolusu. Tshela ugqirha wakho ngoko nangoko ukuba uhlakulela izilonda ekujoliswe kuzo (ukusabela kolusu olukhangeleka ngathi ngamakhonkco), ukuqhiphuka kakhulu okanye ukubola kolusu

 

Iziphumo eziqhelekileyo ezichaphazelekayo I-AZD-9291 powder zezi:

▪ urhudo

▪ irhashalala

▪ ulusu olomileyo

▪ utshintsho kwiinzipho zakho, kubandakanya: ukuba bomvu, ukuthamba, iintlungu, ukudumba, ukukrala, ukwahlukana nebhedi yezikhonkwane, nokuphalazwa kwezikhonkwane

Izilonda zomlomo

▪ ukudinwa

▪ Ukunciphisa ukutya

Ezi ayizizo zonke iziphumo ebezingalindelekanga ezinokubakho ze-AZD-9291 powder. Ngolwazi oluthe kratya, cela ugqirha wakho okanye usokhemesti.

Shayela ugqirha wakho malunga neengcebiso. Unokuxela iziphumo ebezingalindelekanga kwi-FDA ngo-1-800-FDA-1088.

 

isingqiniso

[1] Umnqamlezo we-DA, et al. I-AZD9291, i-EGFR TKI engenakuguqulwa, yoyisa ukunganyangeki phakathi kwe-T790M kwi-EGFR inhibitors kumhlaza wemiphunga. Umhlaza Discov. Ngo-2014 Sep; 4 (9): 1046-61.

[2] Finlay MR, okqhubekayo. Ukufunyanwa kwe-inhibitor ye-EGFR enamandla kunye nokukhetha (AZD9291) kokubini kokukhuthaza kunye ne-T790M yokuchasana nokuchasana okusindisa uhlobo lwasendle lwe-receptor. UJ Med Chem. 2014 Oktobha 23; 57 (20): 8249-67.

[3] U-X, uZhang ZY, et al. "I-anthraquinone derivative shikonin ehambelana ne-AZD9291 xa ithelekiswa neeseli ze-WTEGFR ze-NSCLC ngohlobo lweoksijini olusebenzayo oluhambelana ne-endoplasmic reticulum stress." Unyango lwezonyango. 2020; 68: 153189. IINKCUKACHA:

[4] URichtmann S, uWilkens D, okqhubekayo. "I-FAM83A kunye ne-FAM83B njenge-Prognostic Biomarkers kunye neThagethi eNtsha yokuNyanga kwi-NSCLC." Umhlaza (iBasel). 2019 ngoMeyi 11; 11 (5). IPH: E652. IINKCUKACHA:

[5] UCheriyan VT, uAlsaab H, et al. "Umsebenzi we-CARP-1 osebenzayo wokulinganisa ulungelelwaniso nokujolisa kwe-BRAF kwii-cancer zomhlaza ezingasencinci." Ukhenketho. 2018 Julayi 3; 9 (51): 29680-29697. IINKCUKACHA:

[6] UDarren Cross1, uSue Ashton1, uCaroline Nebhan2 et al. I-AZD9291: Isiphelo sesithathu esingenakuguqulwa, esinamandla kunye nesikhethiweyo sesithathu se-tyrosine kinase inhibitor (TKI) ejolise kwi-EGFR activating (EGFRm +) kunye nokumelana (T790M) kuguquko kwi-lung adenocarcinoma ephezulu. Umhlaza weCancer Ther 2013; 12 (11 Suppl): A109.

[7] Liu YN,. Njl. Al. Ukuxhathisa okufumanekayo kwi-EGFR tyrosine kinase inhibitors kulamla ngokusetyenziswa kwakhona kwe-STC2 / JUN / AXL ukubonisa umhlaza wemiphunga, Int J Cancer, 2019, Jun 4 PMID: 31162839